InvestorsHub Logo
Followers 46
Posts 1362
Boards Moderated 0
Alias Born 08/09/2015

Re: None

Thursday, 10/27/2016 10:32:54 PM

Thursday, October 27, 2016 10:32:54 PM

Post# of 459493
A rehash of the Biogen collaboration, etc.:

Biogen is investigating whether Avxl 2-73 is useful in restoring the myelin sheath or providing some alternative to protecting neurons in place of the myelin sheath.

http://www.webmd.com/multiple-sclerosis/guide/ms-or-als#1:

''Nerve cells in your body are wrapped in thin coverings called myelin sheaths. They protect these cells, similar to how insulation protects electrical wires.

When you have MS, your body attacks the myelin sheaths in your brain and spinal cord.''

MS is but one of the demyelinating diseases being looked at.

Biogen will have to either acquire patent rights from Anavex or do a partnership with Anavex if it desires to commercially pursue the use of AVXL 2-73.

Biogen is not expending the effort of this investigation just for the heck of it. This investigation is expensive. Many people within Biogen that have expertise have mulled this over very carefully. This is not to say that succes by Biogen in its efforts here for treating demyelinating diseases is in any way a given, but it definitely gives a great deal of credibility to the Anavex science. Biogen's decision was not lighty made.

Another way to look at the deal, is that Biogen is doing at its expense what Anavex would otherwise have to do at its expense to gain approval from the FDA to use AVXL 2-73 for MS and other demyelinating diseases.

What does Anavex have to lose in this Biogen deal? What does Anavex have to gain? Is Anavex a better bet today because of the Biogen deal? Is it a better bet for other reasons -- Michael Fox Foundation (Parkinson's study), the Rett Syndrome Foundation (Rhett Syndrome study). Should investors be willing to take a risk along with Biogen, the Michael Fox Foundation, and the Rett Foundation? All of the entities mentioned have put their money on the line along with Anavex as well as the the Australian Government relative to Alzheimer's.

With all of these developments, would you be surprised to see the Anavex share price trade in its higher ranges? I would not.




Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News